Health Technology Clinical Committee
Final Findings and Decision

Topic: Extracorporeal shock wave therapy for musculoskeletal conditions

Meeting date: March 17, 2017
Final adoption: May 19, 2017

Meeting materials and transcript are available on the HTA website:
www.hca.wa.gov/about-hca/health-technology-assessment/meetings-and-materials

Number and coverage topic:
20170317A – Extracorporeal shock wave therapy for musculoskeletal conditions

HTCC coverage determination:
Extracorporeal shock wave therapy for musculoskeletal conditions is not a covered benefit.

HTCC reimbursement determination:

  Limitations of coverage: N/A

  Non-covered indicators: N/A

Agency contact information:

<table>
<thead>
<tr>
<th>Agency</th>
<th>Phone Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Labor and Industries</td>
<td>1-800-547-8367</td>
</tr>
<tr>
<td>Public Employees Health Plan</td>
<td>1-800-200-1004</td>
</tr>
<tr>
<td>Washington State Medicaid</td>
<td>1-800-562-3022</td>
</tr>
</tbody>
</table>
HTCC coverage vote and formal action:

**Committee decision**

Based on the deliberations of key health outcomes the committee decided that it had the most complete information: a comprehensive and current evidence report, public comments, and state agency utilization information. The committee discussed and voted on the evidence for use of extracorporeal shock wave therapy for these conditions compared to current alternative strategies. A majority of members voted extracorporeal shock wave therapy was unproven for efficacy and cost-effectiveness. The committee considered the evidence and gave greatest weight to the evidence it determined, based on objective factors, to be the most valid and reliable.

Based on these findings, the committee voted to not cover extracorporeal shock wave therapy for musculoskeletal conditions.

<table>
<thead>
<tr>
<th>Extracorporeal shock wave therapy for musculoskeletal conditions</th>
<th>Not covered</th>
<th>Covered under certain conditions</th>
<th>Covered unconditionally</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>8</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

**Discussion**

N/A

**Limitations**

N/A

**Action**

The committee checked for availability of a Medicare national coverage decision (NCD). Medicare does have a NCD for extracorporeal shock wave therapy for musculoskeletal conditions.

The committee discussed clinical guidelines identified for extracorporeal shock wave therapy. The chair noted the committee’s decision varied with many of them due to heterogeneity in the conditions addressed.

Clinical guidelines from the following organizations were reviewed:

- Occupational medicine practice guidelines (2011), American College of Occupational and Environmental Medicine (ACOEM), Ankle and Foot Disorders
- Occupational medicine practice guidelines (2012), American College of Occupational and Environmental Medicine (ACOEM), Elbow Disorders
- Knee Disorders, American College of Occupational and Environmental Medicine (ACOEM)
- Shoulder Injury Medical Treatment Guidelines (2015), Colorado Division of Workers’ Compensation
- Guideline for the Diagnosis and Treatment of Subacromial Pain Syndrome: A multidisciplinary review by the Dutch Orthopedic Association (2014), Dutch Orthopedic Association
• Common Overuse Tendon Problems: Review and Recommendation for Treatment (2005), American Academy of Family Practice

• The Diagnosis and Treatment of Heel Pain: A Clinical Practice Guideline (2010), American College of Foot and Ankle Surgeons

The committee chair directed HTA staff to prepare a findings and decision document on extracorporeal shock wave therapy for musculoskeletal conditions for public comment; followed by consideration for final approval at the next public meeting.

Health Technology Clinical Committee Authority:

Washington State’s legislature believes it is important to use a science-based, clinician-centered approach for difficult and important health care benefit decisions. Pursuant to chapter 70.14 RCW, the legislature has directed the Washington State Health Care Authority (HCA), through its Health Technology Assessment (HTA) program, to engage in an evaluation process that gathers and assesses the quality of the latest medical evidence using a scientific research company and that takes public input at all stages.

Pursuant to RCW 70.14.110 a Health Technology Clinical Committee (HTCC) composed of eleven independent health care professionals reviews all the information and renders a decision at an open public meeting. The Washington State HTCC determines how selected health technologies are covered by several state agencies (RCW 70.14.080-140). These technologies may include medical or surgical devices and procedures, medical equipment, and diagnostic tests. HTCC bases its decisions on evidence of the technology’s safety, efficacy, and cost effectiveness. Participating state agencies are required to comply with the decisions of the HTCC. HTCC decisions may be re-reviewed at the determination of the HCA Administrator.